INOVIO COVID-19 Vaccine Trial Begins at Penn Medicine and the Perelman School of Medicine

Penn Medicine is a participant in the Phase I safety and immunogenicity clinical trial of INO-4800, a DNA vaccine designed to prevent COVID-19 infection. Approved by the U.S. Food and Drug Administration (FDA) on April 6, Phase I clinical testing of the vaccine started immediately, with first dosing planned to begin in up to 40 healthy volunteers the same day.